Claudio Mussolino

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8173528/publications.pdf

Version: 2024-02-01

55 papers	3,103 citations	331670 21 h-index	233421 45 g-index
59 all docs	59 docs citations	59 times ranked	3942 citing authors

#	Article	IF	Citations
1	A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Research, 2011, 39, 9283-9293.	14.5	648
2	Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells. Nucleic Acids Research, 2013, 41, e63-e63.	14.5	246
3	Refining strategies to translate genome editing to the clinic. Nature Medicine, 2017, 23, 415-423.	30.7	213
4	Novel Adeno-Associated Virus Serotypes Efficiently Transduce Murine Photoreceptors. Journal of Virology, 2007, 81, 11372-11380.	3.4	210
5	Streptococcus thermophilus CRISPR-Cas9 Systems Enable Specific Editing of the Human Genome. Molecular Therapy, 2016, 24, 636-644.	8.2	204
6	Inactivation of Hepatitis B Virus Replication in Cultured Cells and In Vivo with Engineered Transcription Activator-Like Effector Nucleases. Molecular Therapy, 2013, 21, 1889-1897.	8.2	191
7	TALE nucleases: tailored genome engineering made easy. Current Opinion in Biotechnology, 2012, 23, 644-650.	6.6	188
8	TALENs facilitate targeted genome editing in human cells with high specificity and low cytotoxicity. Nucleic Acids Research, 2014, 42, 6762-6773.	14.5	165
9	Engineered zinc finger nickases induce homology-directed repair with reduced mutagenic effects. Nucleic Acids Research, 2012, 40, 5560-5568.	14.5	160
10	DNA Damage: From Threat to Treatment. Cells, 2020, 9, 1665.	4.1	99
11	Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq. Cell Stem Cell, 2021, 28, 1136-1147.e5.	11.1	95
12	Zincâ€fingerâ€based transcriptional repression of rhodopsin in a model of dominant retinitis pigmentosa. EMBO Molecular Medicine, 2011, 3, 118-128.	6.9	72
13	RNA guides genome engineering. Nature Biotechnology, 2013, 31, 208-209.	17.5	70
14	Designer epigenome modifiers enable robust and sustained gene silencing in clinically relevant human cells. Nucleic Acids Research, 2018, 46, 4456-4468.	14.5	63
15	Inhibition of Ocular Neovascularization by Hedgehog Blockade. Molecular Therapy, 2006, 13, 573-579.	8.2	44
16	Traceless Targeting and Isolation of Gene-Edited Immortalized Keratinocytes from Epidermolysis Bullosa Simplex Patients. Molecular Therapy - Methods and Clinical Development, 2017, 6, 112-123.	4.1	40
17	On target? Tracing zinc-finger-nuclease specificity. Nature Methods, 2011, 8, 725-726.	19.0	35
18	Automated generation of gene-edited CAR TÂcells at clinical scale. Molecular Therapy - Methods and Clinical Development, 2021, 20, 379-388.	4.1	33

#	Article	IF	Citations
19	Correction of IVS I-110(G>A) Î²-thalassemia by CRISPR/Cas-and TALEN-mediated disruption of aberrant regulatory elements in human hematopoietic stem and progenitor cells. Haematologica, 2019, 104, e497-e501.	3.5	32
20	Improved bi-allelic modification of a transcriptionally silent locus in patient-derived iPSC by Cas9 nickase. Scientific Reports, 2016, 6, 38198.	3.3	29
21	Editing CCR5: A Novel Approach to HIV Gene Therapy. Advances in Experimental Medicine and Biology, 2015, 848, 117-130.	1.6	25
22	Disruption of HIV-1 co-receptors CCR5 and CXCR4 in primary human TÂcells and hematopoietic stem and progenitor cells using base editing. Molecular Therapy, 2022, 30, 130-144.	8.2	23
23	TALEN-mediated functional correction of human iPSC-derived macrophages in context of hereditary pulmonary alveolar proteinosis. Scientific Reports, 2017, 7, 15195.	3.3	22
24	Genome and Epigenome Editing to Treat Disorders of the Hematopoietic System. Human Gene Therapy, 2017, 28, 1105-1115.	2.7	20
25	Proven and novel strategies for efficient editing of the human genome. Current Opinion in Pharmacology, 2015, 24, 105-112.	3.5	18
26	Preclinical Evaluation of a Novel TALEN Targeting CCR5 Confirms Efficacy and Safety in Conferring Resistance to HIVâ€1 Infection. Biotechnology Journal, 2021, 16, e2000023.	3.5	18
27	Rescue of DNA-PK Signaling and T-Cell Differentiation by Targeted Genome Editing in a prkdc Deficient iPSC Disease Model. PLoS Genetics, 2015, 11, e1005239.	3.5	17
28	Inhibition of replication of hepatitis B virus using transcriptional repressors that target the viral DNA. BMC Infectious Diseases, 2019, 19, 802.	2.9	15
29	HIV Gene Therapy: An Update. Human Gene Therapy, 2021, 32, 52-65.	2.7	13
30	Recent Approaches for Manipulating Globin Gene Expression in Treating Hemoglobinopathies. Frontiers in Genome Editing, 2021, 3, 618111.	5.2	12
31	Chimerization Enables Gene Synthesis and Lentiviral Delivery of Customizable TALE-Based Effectors. International Journal of Molecular Sciences, 2020, 21, 795.	4.1	10
32	Transcription Activator-Like Effector (TALE) Nucleases and Repressor TALEs for Antiviral Gene Therapy. Current Stem Cell Reports, 2015, 1, 1-8.	1.6	9
33	Targeted genome editing restores T cell differentiation in a humanized X-SCID pluripotent stem cell disease model. Scientific Reports, 2017, 7, 12475.	3.3	9
34	The Scope for Thalassemia Gene Therapy by Disruption of Aberrant Regulatory Elements. Journal of Clinical Medicine, 2019, 8, 1959.	2.4	9
35	Precise Epigenome Editing on the Stage: A Novel Approach to Modulate Gene Expression. Epigenetics Insights, 2018, 11, 251686571881883.	2.0	7
36	Quantitative Evaluation of Chromosomal Rearrangements in Primary Gene-Edited Human Stem Cells by Preclinical CAST-Seq. SSRN Electronic Journal, 0, , .	0.4	7

#	Article	IF	Citations
37	Generation of TALE-Based Designer Epigenome Modifiers. Methods in Molecular Biology, 2018, 1767, 89-109.	0.9	5
38	Genome Editing of the SNAI1 Gene in Rhabdomyosarcoma: A Novel Model for Studies of Its Role. Cells, 2020, 9, 1095.	4.1	5
39	Delivery of Designer Epigenome Modifiers into Primary Human T Cells. Methods in Molecular Biology, 2018, 1767, 189-203.	0.9	3
40	Fast and Quantitative Identification of Ex Vivo Precise Genome Targeting-Induced Indel Events by IDAA. Methods in Molecular Biology, 2019, 1961, 45-66.	0.9	3
41	TALEN mediated gene editing in a mouse model of Fanconi anemia. Scientific Reports, 2020, 10, 6997.	3.3	3
42	Gene Therapy â€œMade in Germanyâ€• A Historical Perspective, Analysis of the Status Quo, and Recommendations for Action by the German Society for Gene Therapy. Human Gene Therapy, 2021, 32, 987-996.	2.7	3
43	483. Epigenetic Silencing of Hepatitis B cccDNA In Vitro and In Vivo Using AAV-Delivered Engineered Repressor Transcription Activator-Like Effector. Molecular Therapy, 2015, 23, S192.	8.2	2
44	A versatile reporter system for multiplexed screening of effective epigenome editors. Nature Protocols, 2020, 15, 3410-3440.	12.0	2
45	692. Genome Editing for Personalized Gene Therapy of IVSI-110 Beta-Thalassemia. Molecular Therapy, 2016, 24, S274.	8.2	1
46	The Use and Development of TAL Effector Nucleases. Advances in Experimental Medicine and Biology, 2016, , 29-50.	1.6	1
47	118. Inhibition of Hepatitis B Virus Replication In Vivo Following Delivery of Antiviral TALENs With Recombinant Adeno-Associated Viral Vectors. Molecular Therapy, 2015, 23, S49.	8.2	0
48	125. Engineered Nucleases-Mediated In Situ Correction of a Genetic Defect By Homologous Recombination Into the Native Locus. Molecular Therapy, 2015, 23, S51-S52.	8.2	0
49	325. Targeted Gene Addition Strategies for the Treatment of X-Linked Lymphoproliferative Disease. Molecular Therapy, 2016, 24, S130-S131.	8.2	0
50	Targeted gene addition strategies for the treatment of X-linked lymphoproliferative disease. Lancet, The, 2016, 387, S21.	13.7	0
51	Genome Editing in Transfusion Medicine. Stem Cells and Development, 2019, 28, 714-714.	2.1	0
52	Gene Therapy Getting Personal: Mutation-Specific Editing and Gene Addition Strategies for Î²-Thalassaemia. Hemoglobin, 2019, 43, 330-330.	0.8	0
53	Spotlight on gene therapy in Germany. Gene Therapy, 2021, 28, 471-472.	4.5	0
54	Designer Effectors for Editing and Regulating Complex Genomes. , 2017, , 137-157.		0

#	Article	IF	Citations
55	A Highly Efficient and GMP Compliant Protocol to Manufacture CCR5 Edited Cells to Treat HIV Infection. Blood, 2018, 132, 5795-5795.	1.4	0